First TYK2 Inhibitor for Psoriasis Wins FDA Approval
The FDA approved the first-in-class oral tyrosine kinase 2 (TYK2) inhibitor deucravacitinib (Sotyktu) for moderate-to-severe plaque psoriasis, Bristol Myers Squibb announced. The indication limits use to adults who are candidates for systemic therapy or phototherapy. Deucravacitinib is not recommended for use with other immunosuppressant drugs. “Sotyktu has the potential to become the new standard-of-care oral […]